17th Oct 2014 09:23
LONDON (Alliance News) - GlaxoSmithKline PLC on Friday said positive results from a third lung function study on its Anoro Ellipta chronic obstructive pulmonary disease treatment have been published in the Respiratory Medicine journal.
The study showed a statistically significant improvement of the product for the primary endpoint measurement of lung function, along with an improvement also in lung function at the end of the treatment period, in comparison to using tiotropium bromide, a treatment used to prevent the symptoms of COPD, emphysema or chronic bronchitis.
"We are pleased to announce the publication of these important data comparing Anoro Ellipta with tiotropium," said Darrell Baker, Senior Vice President and Head of Glaxo's Global Respiratory Franchise.
"These results support the lung function benefit of Anoro Ellipta in the treatment of appropriate patients with COPD. We hope the publication will inform physicians as they consider which treatment option is best to meet their individual patient?s needs," Baker added.
Glaxo shares were up 1.7% on Friday to 1,346.75 pence.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2014 Alliance News Limited. All Rights Reserved.
Related Shares:
Glaxosmithkline